Drug Database
ME

meningococcus B & C vaccine

✓ Approved

Abivax · Vaccine · Vaccine

What is meningococcus B & C vaccine?

meningococcus B & C vaccine is a vaccine developed by Abivax. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

CompanyAbivax
Drug ClassVaccine
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, Abivax

Therapeutic Indications

meningococcus B & C vaccine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsMeningococcal bacteraemia✓ Approved

Related Research Articles

PubMedJournal of the colleges of medicine of South Africa2026-11-11

The molecular epidemiology of human respiratory syncytial virus in a tertiary paediatric hospital between 2020 and 2024.

Maseko Moepeng J MJ, Joseph Rageema R, Korsman Stephen N J SNJ, Valley-Omar Ziyaad Z et al.

Respiratory syncytial virus (RSV) is a leading cause of respiratory illness in young children, contributing significantly to morbidity and mortality and placing a substantial burden on resource-limited healthcare systems. Molecular epidemiological data from sub-Saharan Africa remain limited. This study aimed to investigate the genetic diversity and evolution of RSV in a paediatric population in Cape Town, South Africa, from September 2020 to June 2024. Respiratory syncytial virus-positive respiratory samples with a cycle threshold (Ct) < 30 from patients at Red Cross War Memorial Children's Hospital were sequenced and analysed. Phylogenetic analysis of the partial RSV genome (F and G genes) was conducted using reference sequences derived from a global sequence database. Mutational profiles were assessed for relevance to monoclonal antibody and vaccine effectiveness. Of the 100 selected samples, 42 were sequenced, and 40 had sufficient coverage for analysis. Sequencing failure was associated with higher Ct values, older sample age and suboptimal storage at -20°C. Respiratory syncytial virus-A predominated (78.6%), with A.D.5.1 as the dominant lineage; RSV-B strains (16.7%) clustered within B.D.E.1 and B.D.4.1. Genotypes GA2.3.5 (RSV-A) and GB5.0.5a (RSV-B) were observed, consistent with post-pandemic global trends. G-gene analysis revealed multiple substitutions (G224E, I134K, K262E) suggestive of immune pressure. The F-gene remained more conserved; substitutions such as T122A, S211N and S389P were detected but were not linked to reduced susceptibility to monoclonals. This study demonstrated the co-circulation of genetically diverse RSV-A and RSV-B lineages in children between 2020 and 2024. No established resistance-associated substitutions to currently licensed RSV monoclonal antibodies were identified. Continued genomic surveillance is warranted to monitor RSV evolution. Continued genomic surveillance is essential to strengthen molecular epidemiology and guide public health preparedness.

PMID 43011429
Read full article →
PubMedmSphere2026-11-11

Genetic detoxification of an unencapsulated Neisseria meningitidis strain enhances potency of outer membrane vesicle vaccines and cross-reactivity of vaccine-specific antibodies.

Matthias Kathryn A KA, Kumova Ogan K OK, Reveille Alexandra A, Bizzell Erica E et al.

Meningococcal serogroup B (MenB) detergent-detoxified outer membrane vesicle (dOMV) vaccines demonstrate high effectiveness against the homologous production strain but confer limited cross-protection to heterologous strains. We previously reported that dOMVs isolated from a MenB strain deleted for the proteins PorA, PorB, and RmpM (ΔABR) elicited bactericidal antibodies with a greater breadth of coverage, but of lower overall titer, compared to wild-type (WT) dOMV-induced antibodies. Low ΔABR dOMV potency was associated with pronounced vesicular deterioration and lower levels of lipooligosaccharide (LOS) and capsular polysaccharide (Cps) relative to WT dOMVs, phenotypes resulting from detergent detoxification procedures required to limit LOS-induced toxicity. In this study, we engineered genetically detoxified ΔABR strains that were deleted singly for the lauroyl acyltransferase LpxL1 (ΔABRL) or in tandem for the Cps polysialyltransferase SiaD (ΔABRSL). Genetically detoxified, detergent-extracted OMVs (eOMVs) from ΔABRL and ΔABRSL retained vesicular structure and elicited functional antibodies with increased cross-reactivity compared to ΔABR and ΔABRL dOMVs when administered to rabbits. Antibody seropositivity and cross-reactivity were similarly increased in mice vaccinated with ΔABRL eOMVs vs ΔABRL dOMVs. ΔABRSL eOMV potency was higher than that of ΔABRL eOMVs, suggesting a role for Cps in suppressing antibody responses. Immunization with eOMVs was associated with trends toward improved murine T helper cell responses and elicitation of higher proportions of conformational antibodies that may have contributed to improved bactericidal activity. ΔABRSL eOMVs additionally showed decreased toxicity compared to WT and ΔABR dOMVs when tested in vitro, supporting further study as a vaccine candidate. The ability to target multiple serogroup B Neisseria meningitidis strains with a single vesicle vaccine is complicated by the diversity of antigens that span the bacterial surface. We previously reported that vesicles isolated from meningococcal strains deleted for the major antigenically diverse surface proteins elicited functional antibodies that could kill a large number of N. meningitidis strains though at relatively low titers. Low potency of the mutant vaccines was associated with a breakdown of the vesicular membrane upon detergent treatment, a process necessary to diminish endogenous endotoxin levels and ensure vaccine safety. In this study, we demonstrate that we can retain high cross-reactivity of anti-vesicle antibodies without decreasing the potency of the host immune response through genetic detoxification of the meningococcal vaccine strain. By preventing the formation of the complete endotoxin structure, we are able to isolate vesicles that are safe and immunogenic without the requirement for detergent detoxification.

PMID 43012508
Read full article →
PubMedThe Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology2026-11-11

Castor Oil Plus Polyethylene Glycol Electrolyte for Colonoscopic Bowel Preparation: A Prospective 3-Arm Randomized Controlled Trial.

Li Yanxia Y, Wang Wenjuan W, Jiang Xiaoda X, Huang Xu X et al.

The aim of this study was to compare 2 reduced-volume polyethylene glycol (PEG) electrolyte solution regimens combined with castor oil (CaO) with conventional 3-L PEG for bowel preparation before colonoscopy. This single-center, prospective, randomized, endoscopist-blinded trial enrolled 720 adults undergoing elective colonoscopy. Participants were assigned to receive 3-L PEG (group A), 2-L PEG plus 40 mL of CaO (group B), or 1-L PEG plus 40 mL of CaO (group C). The primary outcome was right-colon cleansing assessed using the Boston Bowel Preparation Scale (BBPS). Secondary outcomes included BBPS scores for other colonic segments and the total colon, Colon Endoscopic Bubble Scale (CEBuS) scores, adenoma detection rate (ADR), and preparation-related adverse events. Complete colonoscopy was achieved in 691 participants. Mean right-colon BBPS scores were 2.03 Å} 0.57, 2.45 Å} 0.53, and 2.31 Å} 0.27 in groups A, B, and C, respectively (overall P = .013). The score was higher in group B than in group A (P = .048), whereas the difference between groups B and C was not statistically significant (P = .096). Group B also had a lower CEBuS score than group A (1.02 Å} 0.42 vs. 1.73 Å} 0.16; P = .048). ADRs were 22.1%, 34.5%, and 29.9% in groups A, B, and C, respectively (overall P = .012), with a higher rate in group B than in group A (P = .038). Most pairwise differences in adverse events were not significant. No serious preparation-related adverse events occurred. The 2-L PEG plus CaO regimen improved right-colon cleansing and bubble clearance and was associated with a higher ADR compared with conventional 3-L PEG.

PMID 43012342
Read full article →
PubMedThe Journal of organic chemistry2026-11-11

One-Pot Synthesis of Benzofuropyridines and Benzofuroquinolines via Tandem Cycloaddition-Cyclization of Halopyridine- and Haloquinoline N-Oxides with Arynes.

Sharma Pragati P, Choudhary Shubhanjali S, Joshi Sindhuja S, Bose Shubhankar S et al.

A transition-metal-free approach for the one-pot synthesis of benzofuro[3,2-c]pyridines, benzofuro[3,2-b]pyridines, and benzofuro[3,2-c]quinolines has been developed by the reaction of suitably chlorinated pyridine N-oxides and quinoline N-oxides with arynes. A tandem three-step protocol involving the cycloaddition-rearrangement-SNAr cyclization by the reaction of 4-chloropyridine N-oxides with in situ generated aryne intermediates provided benzofuro[3,2-c]pyridines. The Cl substitution at the C-3 position of pyridine N-oxides afforded benzofuro[3,2-b]pyridines. The methodology worked successfully with 2-aryl-4-chloroquinoline N-oxides, affording 2-arylbenzofuro[3,2-c]quinolines. The transition-metal-free strategy comprising a multistep cascade is amenable to a modular synthesis of diversely fused benzofuropyridines and benzofuroquinolines.

PMID 43012293
Read full article →
PubMedBMC oral health2026-11-11

The impact of smoking and diabetes on periodontitis grade: A retrospective cross-sectional observational study.

Steinbrenner Gina G, Lingwal Neelam N, Sayed Nihad El NE, Eickholz Peter P

Evaluation of the amount of periodontitis patients whose grade is determined by smoking and/or diabetes. All charts of patients scheduled for active periodontal treatment at Goethe University Frankfurt, Germany, Dept. of Periodontology from November 2004 on were screened until data saturation was reached, and 402 charts met the inclusion criteria. Charts were analysed and patients reclassified according to the 2018 classification of periodontal diseases. Grade A/B was also assigned according to Dietrich et al. 2019. Four-hundred-two patients (age: 56.9 ± 11.4 years; 208 females; 68 active smokers; 22: 1-9 cigarettes/day; 46: ≥10 cigarettes/day; 29 diabetics, 18: HbA1c < 7%, 11: HbA1c ≥ 7%; 7 stage II, 234 stage III, 161 stage IV, 0 grade A, 179 grade B [Tonetti et al. 2018], 10 grade A, 169 grade B [Dietrich et al. 2019], 223 grade C) contributed 9,318 teeth and 221 dental implants. No heavy smoker (≥ 10 cigarettes/day) suffered from HbA1c ≥ 7%. Generalised stage III periodontitis grade C was exclusively determined by smoking in 7 and by diabetes in 3 cases. In this convenience periodontitis sample in generalised stage III periodontitis, grade C was rarely determined exclusively by smoking (7 cases [7%]) or diabetes (3 cases [3%]). Only 10 patients were assigned to different grades according to Dietrich et al. 2019 (2.5%). March 11, 2024 registered in the German Register of Clinical Studies (Deutsches Register Klinischer Studien: DRKS) DRKS00033633.

PMID 43009922
Read full article →
PubMedInternational journal of women's health2026-11-11

Comparison of Pregnancy Outcomes from Fresh Transfer of High-Quality Single Blastocysts in Women of Different Ages: A Retrospective Study.

Wu Yanhong Y, Wu Shenghao S, Chen Haoying H, Su Weijue W et al.

To compare pregnancy and neonatal outcomes following fresh high-quality single blastocyst transfer (SBT) across different maternal age groups. This retrospective cohort study included 4352 women who underwent fresh high-quality SBT and were divided into three age groups: <30 years (Group A, n = 1939), 30-34 years (Group B, n = 1801), and 35-37 years (Group C, n = 612). Baseline characteristics, pregnancy outcomes, and neonatal outcomes were compared across the groups. Non-live birth was the prespecified primary outcome. For secondary and exploratory outcomes, P values were adjusted for multiple comparisons using the Bonferroni method. Women in Group A had a significantly higher live birth rate than those in Group C (56.88% vs 43.79%; P < 0.001). No significant differences were observed between Groups A and B. The miscarriage rate in Group C (20.94%) was significantly higher than that in Group A (11.48%; P < 0.001); however, the difference compared with Group B (14.06%) did not remain significant after Bonferroni correction. Exploratory differences in preterm birth, gestational diabetes mellitus, and birth defects were also not statistically significant after correction. Multivariable analysis showed that maternal age 35-37 years was independently associated with higher odds of non-live birth (OR = 1.539, 95% CI 1.220-1.942) and adverse pregnancy outcomes (OR = 1.515, 95% CI 1.135-2.024), whereas age 30-34 years was not. Among women undergoing fresh high-quality SBT, those aged 30-34 years achieved pregnancy outcomes comparable to those of women aged <30 years, whereas women aged 35-37 years had significantly lower live birth rates and higher miscarriage rates. These findings reflect age-related differences within the SBT population rather than a comparison between transfer strategies. Large-scale prospective multicenter randomized trials are warranted.

PMID 43011522
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about meningococcus B & C vaccine